3rd ESTRO Forum 2015 S315 HNSCC is feasible while respecting strict dose constraints to OARs. By correcting for morphological and biological tumor changes during RT, higher conformity is ensured between the FDG uptake and the dose distributions. Clinical studies must be conducted to evaluate the acute and chronic toxicities and the tumor response of such a strategy.
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Target-selective radio-sensitization in head and neck tumors by the novel HYPERcollar3D hyperthermia applicator M.M. Paulides 1 , Z. Rijnen 1 , P. Togni 1 , G.M. Verduijn 1 , G.C. Van Rhoon 1 1 Erasmus MC -Cancer Institute, Radiation Oncology, Rotterdam, The Netherlands Purpose/Objective: Current treatment of advanced cancer of the head and neck is unsatisfactory in terms of outcome and the toxicity of current treatments are severe. Phase III clinical trials have shown that hyperthermia (heating in the range of 40-44°C for one hour) is a potent sensitizing agent of radiotherapy, which is achieved without additional toxicity [1] [2] [3] . To enable heat-sensitization also in target regions at deep locations, we developed the HYPERcollar and showed in 45 patients that inducing hyperthermia in tumors located deeply and laterally in the head and neck region is feasible and has potential. Over the years, we further introduced an adaptive hyperthermia strategy based on electromagnetic field simulations. In this study, we analyze the HYPERcollar3D that is a redesigned version of the HYPERcollar aimed at improving heating quality, heating reproducibility and patient comfort. Materials and Methods: In the HYPERcollar3D, patient comfort and treatment accuracy/stability are improved by splitting the waterbolus functions into a stable outer part and a patient conformal inner part. Patient positioning according to the CT resembles that of radiotherapy and is obtained by immobilization and a laser alignment procedure. Based on a mechanical redesign, we performed parameter studies using electromagnetic simulator SEMCAD-X (v. 14.8.6) to investigate further improvement by increasing the number of antennas and their locations.
Results:
The simulation studies showed that higher number of antennas, and their repositioning, allows for a substantially improved treatment quality. All improvements combined enable a predicted reduction of hotspot importance prominence (hot-spot target quotient (HTQ)) by 32%. Combining all systems improvements, simulations predict that a doubling of the clinically applied power to the target can be achieved. After clinical introduction, two patients (nasopharynx ca. and a neck node metastasis) have been treated with the HYPERcollar3D. Validation of heating performance by invasive thermometry in the tumor proved not possible but, in both patients, the scheduled treatments of 75 minutes could be completed using a mean applied power of 350-400W. In addition, the estimated SAR based on the realtime measured powers/phases of the signals was 90W-200W/kg, which is beyond the long term average applied SAR using the conventional HYPERcollar, i.e. 75W/kg. Conclusions: Although the improvement still has to be validated by invasive temperature measurements in the tumor, these results are very reassuring that the HYPERcollar3D will provide a significant improvement in treatment quality. Hyperthermia is currently used as a standard addition to radiotherapy for patients that are reirradiated. A protocol for a clinical study in primary tumors is being finalized. 
